Clorox: The consumer products giant saw a huge increase in profits. It is also recovering from last year's cyberattack. “Things are back online and there is tremendous demand for your product,” Jim said quickly at the Friday morning meeting. Tesla: The leader in electric vehicles issued a recall for 2.2 million cars due to a warning light issue. Remember, our Super Six means ditching Tesla; No more Magnificent Seven. Jim said he might not buy the slide. “I urge people to rethink that maybe [Elon Musk] “It's not as interesting as being CEO anymore.” Bristol-Myers Squibb – Shares of the drugmaker rose after better-than-expected earnings and a better-than-expected 2024 outlook. “A five-year plan for Bristol Myers,” Jim said, unless the company can get more drugs to work. CNBC Investor Club members know that Eli Lilly is our favorite pharmaceutical stock. Abbvie: The drugmaker had a mixed quarter, but raised its forecast. Abbvie lost exclusivity on the blockbuster Humira. The stock remains on the rise. “They'll be able to handle the valley,” Jim said. Exxon and Chevron: the two oil majors increased their profits. Chevron rose 3% after raising its dividend following rumors that it would not be able to pay it. Jim said “If you have to own oil, we like Coterra” and own it for the Club. He likes Chevron more than Exxon.
